Dr. Street is a Fellow of the Royal Society of Chemistry, a member of the American Chemical Society, and recently served as a visiting Professor of Chemistry at the University of Nottingham, UK. He received a doctorate from Leeds University in the UK.Covance generates more new drug development data than any other organization in the world. The company offers the industry's broadest and most integrated portfolio of R&D services, offering flexible, milestone-based solutions and full development solutions in clinical pharmacology, early clinical development, and molecule development. About Covance Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies, with annual revenues greater than $2 billion, global operations in more than 30 countries, and more than 11,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com. Forward Looking Statements Statements contained in this press release (and in the webcast announced in this press release), which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue, earnings growth, and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.